Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07106021 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
A Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease, sponsored by Kenai Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT07106021 is a Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease that is actively recruiting participants, run by Kenai Therapeutics. The registered enrollment target is 12 participants, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT07106021, a Phase 1 study of Idiopathic Parkinson´s Disease and Parkinson's Disease, is actively recruiting participants, sponsored by Kenai Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
Conditions Studied
Interventions
- BIOLOGICAL RNDP-001
- DEVICE Syringe Front-Loading Device
Study Locations (3)
Arizona
- University of Arizona - Tucson
California
- Keck Medical Center of University of Southern California - Los Angeles
Ohio
- The Ohio State University Wexner Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07106021
The ClinicalTrials.gov registry entry for NCT07106021 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower). The listed sponsor is Kenai Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 2 interventions - of which RNDP-001 is the first listed.
NCT07106021 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT07106021 about?
NCT07106021 is a clinical study titled "A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease". This clinical trial is designed to test the safety and tolerability of the study intervention, RNDP-001, which will be implanted into the brain of study participants during a surgical procedure.
What is the current status of trial NCT07106021?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-07-17. Estimated completion is 2031-06.
What conditions does trial NCT07106021 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease, Parkinson's Disease.
What interventions are being tested in trial NCT07106021?
The interventions under investigation include: RNDP-001 (BIOLOGICAL), Syringe Front-Loading Device (DEVICE).
Who is sponsoring clinical trial NCT07106021?
This trial is sponsored by Kenai Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07106021 being conducted?
This trial has 3 study locations across Arizona, California, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Infusion of Apomorphine: Long-term Safety Study
ACTIVE NOT RECRUITING · Phase 3
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.